Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here we go again, could get real interesting...
* * $LPTN Video Chart 04-26-16 * *
Link to Video - click here to watch the technical chart video
Be careful Proxy is out for R.S that's why I sold today for 50% loss. I normally do not write but I do not want anyone else to get burn.
.33 AH Could be a gap and run...
* * $LPTN Video Chart 04-14-16 * *
Link to Video - click here to watch the technical chart video
$LPTN recent news/filings
bullish 0.21
$LPTN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$LPTN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/LPTN/company-info
Ticker: $LPTN
$LPTN extra dd links
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LPTN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LPTN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LPTN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/news - http://finance.yahoo.com/q/h?s=LPTN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LPTN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LPTN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LPTN
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LPTN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LPTN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LPTN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LPTN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LPTN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LPTN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LPTN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LPTN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LPTN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LPTN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LPTN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LPTN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LPTN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LPTN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LPTN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LPTN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LPTN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LPTN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LPTN
StockTwits (stocktwits.com): http://stocktwits.com/symbol/LPTN
$LPTN DD Notes ~ http://www.ddnotesmaker.com/LPTN
Good to see LPTN Green Trend and Close above .18, .14 was hopefully the Bottom and won't be revisited any time soon.
LPTN DOWN Again, if it does not hold .14 tomorrow then it better hold .12 or this going to .10 or less for the long term. Tuning in again Tomorrow.
I added a few .17s here last week
Phase 1a Study Results news just Out, more expected April 2016, so still looking for the big news too. Keep it coming LPTN
LPTN Green Close of .19 from recent bottom of .14, next week will reveal if this will be a Sustained Move or Just a Bounce from .14
Looking good , Might try to find entry next week @ 0.17 glty
oversold. news anyday $LPTN .50+ gap up imo
Whats going on with this company? Nice Biotech play down here...
$LPTN Buy and Stay long Per #AmericanBulls > https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=LPTN
$LPTN +11.91% next leg .33
.14 needs to hold/.12 would be new LPTN 52 week low
Not for the Macular Degeneration Late Stage Application that is still under study. Those are the Partnerships we are all waiting to hear about. Would be new and novel application for late stage Macular Degeneration that no other bio has shown yet. Was reversing the damage at this stage, all in the Conference call. If it is reproducible consistently-Watch out.
support here $LPTN Loading Zone
$LPTN had an agreement with Pfizer at one point, I believe it had expired.
LPTN or L Path Website has what the Company is working on and the only thing ready to go is the Macular Degeneration Application. Everything else stated on the Website is Years Away as far as pre-clinical studies, Phase 1, etc development is concerned. If they were able to do all the stuff posted, the stock would not be under 30 cents and they would have $100 Million in Cash instead of Less than 10 Million in Cash. The Conference call, whose content should be found on their website, discussed MOSTLY that, the MD stuff. LPTN overall is a long term or near term Patience Play with some bounce spikes in it for short term Momentum Players. So money can be made either way. Biggest near term run will be IF they announce some Heavy hitting Pharma Partners like Pfizer, etc, for the MD product.
Good Trading to All
$LPTN Polypoidal Choroidal Vasculopathy - Global Clinical Trials Review, H2, 2015
Research and Markets (http://www.researchandmarkets.com/research/vv668j/polypoidal) has announced the addition of the "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" report to their offering. "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" provides an overview of Polypoidal Choroidal Vasculopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Polypoidal Choroidal Vasculopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
http://www.barchart.com/headlines/story/10780905/polypoidal-choroidal-vasculopathy-global-clinical-trials-review-h2-2015
$LPTN Spinal Cord Injury - Pipeline Review H2 2015
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
http://www.barchart.com/headlines/story/11191542/spinal-cord-injury-pipeline-review-h2-2015
$LPTN Diabetic Retinopathy - Pipeline Review, H2 2015 #diabetes Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
http://www.barchart.com/headlines/story/12858711/diabetic-retinopathy-pipeline-review-h2-2015
$LPTN Kidney Fibrosis - Pipeline Review 2015
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. -
http://www.barchart.com/headlines/story/13194842/kidney-fibrosis-pipeline-review-2015
$LPTN Stay Long @ AmericanBulls https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=LPTN
Clearly #CupAndHandle #Chart $LPTN
$LPTN Double Down she is going PARABOLIC from here
$LPTN MSCI Inc upgraded LPATH INC from 1 to 3.
LPTN may have hit bottom but cannot say for sure until it starts to Close Green, Trade Sideways, close Green again per Chart Supports. Can say Big Buys today around .17 which is why that held. 30k, 10k, 5k etc so at least someone is buying. If they are going to announce some new Partnerships with REAL substance as referenced in the last Conference Call, then all good here. If not, then down she goes and the bottom will be way down from here and the chance of a RS increases exponentially.
Looking a lot like its hit a bottom. Thought you sold out (Orion bd post)?
Is the stock HALTED=?????
$lptn next let $.28
$LPTN will explode $.50+ coming any day imo
Well LPTN has not found Bottom yet, Next Support is .12 unless Ticker bounces back to Support of .17
$LPTN Institutional Holder: Sabby Management owns 1,086,171 shares
$LTPN Top Institutional Holders
Holder Shares % Out Value* Reported
Sabby Management, LLC 1,086,171 3.35 206,372 Sep 30, 2015
KCG Holdings, Inc. 148,681 0.46 28,249 Sep 30, 2015
Ancora Advisors, LLC 87,500 0.27 16,625 Sep 30, 2015
Geode Capital Management, LLC 73,584 0.23 13,980 Sep 30, 2015
CALPERS (California-Public Employees Retirement System) 65,300 0.20 12,407 Sep 30, 2015
Vanguard Group, Inc. (The) 60,978 0.19 11,585 Sep 30, 2015
Citadel Advisors LLC 51,225 0.16 9,732 Sep 30, 2015
Goldman Sachs Group, Inc. 30,541 0.09 5,802 Sep 30, 2015
Bank of America Corporation 29,730 0.09 5,648 Sep 30, 2015
Stifel Financial Corporation 13,415 0.04 2,548 Sep 30, 2015
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
Spartan Extended Market Index Fund 62,657 0.19 11,278 Oct 31, 2015
Vanguard Extended Market Index Fund 44,704 0.14 12,517 Jun 30, 2015
Claymore ETF Tr-Wilshire Micro Cap ETF 12,800 0.04 2,304 Oct 31, 2015
Spartan Total Market Index Fund 7,871 0.02 1,416 Oct 31, 2015
Fidelity NASDAQ Composite Index Tracking Stock 3,056 0.01 550 Oct 31, 2015
http://finance.yahoo.com/q/mh?s=LPTN+Major+Holders
$LPTN when news comes $.35+
imo
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
712
|
Created
|
11/19/06
|
Type
|
Free
|
Moderators |
![]() | ||||||||||
![]() Lpath Incorporated 4025 Sorrento Valley Blvd. San Diego, CA 92121 Tel: 858-678-0800 FAX: 858-678-0900 | ||||||||||
Lpath, Inc. is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines. | ||||||||||
![]() | ||||||||||
Lpath, Inc. focuses on the discovery and development of monoclonal antibodies that target bioactive lipids. Numerous lipids that contribute to disease have now been identified through the various efforts of academics and industry. However, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2™ platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities. Lpath has leveraged ImmuneY2 and generated monoclonal antibody drug candidates against several bioactive lipids, including sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), leukotrienes (LTs) and others. Lpath is currently advancing LpathomabTM, a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized to be involved in disorders of the central nervous system (including pain, traumatic brain injury, neurodegeneration), fibrosis, ocular disease and cancer. Lpathomab has demonstrated strong preclinical activity in several animal models of these diseases, including neuropathic pain, diabetic neuropathy, traumatic brain injury and spinal cord injury. Lpathomab is currently in a phase 1 clinical trial. The company is applying ImmuneY2 to other bioactive lipid targets, many of which are involved in important disease processes (e.g. inflammation, cancer, pain, asthma, and others) thereby adding to our pipeline of novel antibody-based drug candidates. Lpath has a broad and deep intellectual property position in the bioactive lipid area, with over 50 issued or pending patents in the U.S., with corresponding international applications. Most of these patents were developed in-house using our proprietary technologies and expertise. Executive Team
| ||||||||||
![]() | ||||||||||
Good read: http://seekingalpha.com/article/412101-why-morgan-joseph-expects-triple-digit-gains-for-this-pfizer-partner ASONEP http://www.clinicaltrials.gov/ct2/show/NCT00661414 Share Structure
Transfer Agent(s) |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |